Chevy Chase Trust Holdings LLC Sells 472 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Chevy Chase Trust Holdings LLC cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,081,677 shares of the biopharmaceutical company’s stock after selling 472 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Bristol Myers Squibb were worth $65,971,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $1,989,525,000. Ameriprise Financial Inc. grew its position in shares of Bristol Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Bristol Myers Squibb by 701.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company’s stock valued at $705,309,000 after purchasing an additional 10,913,708 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Bristol Myers Squibb by 3,880.0% during the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company’s stock valued at $338,088,000 after purchasing an additional 5,827,317 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $257,618,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. Jefferies Financial Group dropped their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $58.00.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $46.97 on Tuesday. The company has a market capitalization of $95.59 billion, a PE ratio of 17.59, a P/E/G ratio of 1.39 and a beta of 0.38. Bristol Myers Squibb Company has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company has a 50 day moving average price of $48.12 and a 200-day moving average price of $54.21.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. Bristol Myers Squibb’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($4.40) earnings per share. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 92.88%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.07% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.